Organic Revenue and Net Income Growth
Zoetis reported a 4% revenue growth and 9% growth in adjusted net income on an organic operational basis.
International Segment Performance
The International segment delivered 6% organic operational revenue growth, with strong performance in both Companion Animal and Livestock segments.
Livestock Segment Growth
The Livestock segment grew 10% in organic operational revenue, marking the third consecutive year of above-market growth, driven by resilient market demand.
Simparica Franchise Success
The Simparica franchise grew 7% operationally, with a strong performance from Simparica Trio, which grew 6% operationally.
New Product Approvals
Zoetis received European approval for Portela, a long-acting monoclonal antibody for feline OA pain, and positive CVMP opinion for Lenivia in Europe.
Cost Discipline and Earnings Growth
Adjusted net income grew 5% operationally and 9% on an organic operational basis, with adjusted diluted EPS growing 7% operationally.